Hereditary neuromuscular disease
MONDO:0100546A heterogeneous group of genetic conditions with Mendelian (autosomal dominant, recessive, or X-linked) or chromosomal etiology that is characterized by progressive muscle degeneration and weakness.
797 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Hope for muscle strength: experimental drug tested for Long-Term use in rare muscular dystrophy
Disease control OngoingThis study tests the long-term safety and effectiveness of an experimental drug called BBP-418 (ribitol) in people with limb-girdle muscular dystrophy type 2I/R9, a rare genetic muscle-weakening disease. Participants who completed a previous study will take BBP-418 orally twice d…
Phase: PHASE3 • Sponsor: ML Bio Solutions, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Experimental gene therapy aims to halt devastating brain disease in infants
Disease control TerminatedThis study tests a gene therapy called PBKR03 for babies with early infantile Krabbe disease, a severe genetic disorder that damages the brain and nerves. The treatment delivers a working copy of the GALC gene to the brain and body. Researchers will check safety and find the best…
Phase: PHASE1, PHASE2 • Sponsor: Gemma Biotherapeutics • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Vertex tests long-term safety of VX-670 for muscle disease
Disease control ENROLLING_BY_INVITATIONThis study tests the long-term safety and effectiveness of an experimental drug called VX-670 in adults with myotonic dystrophy type 1 (DM1). Participants who completed a previous VX-670 study can join. The drug is given through a vein, and researchers will monitor side effects a…
Phase: PHASE2 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug aims to tackle rare brain disease
Disease control OngoingThis early-stage trial tests a single injection of ARO-ATXN2 in 36 adults with spinocerebellar ataxia type 2, a rare genetic disorder that affects movement and coordination. The main goal is to see if the drug is safe and how the body processes it. Participants are randomly assig…
Phase: PHASE1 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for duchenne? experimental drug BMN 351 enters human testing
Disease control OngoingThis early-stage trial is testing a drug called BMN 351 in 18 boys aged 4 to 10 with Duchenne muscular dystrophy who have a specific genetic change. The drug is designed to help the body produce a shorter but still useful version of the muscle protein dystrophin. The main goal is…
Phase: PHASE1, PHASE2 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Drooling treatment study pulled before it began
Disease control TerminatedThis study planned to test whether injecting botulinum toxin (Botox) into the salivary glands could reduce drooling in people with true bulbar palsy, a condition that causes swallowing problems after a brain stem injury. The trial was designed to compare the injections against st…
Phase: NA • Sponsor: houyajing • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug could slow rare brain disease that steals balance
Disease control OngoingThis phase 3 trial tests whether the drug troriluzole can slow the progression of spinocerebellar ataxia, a rare genetic disorder that affects coordination and balance. About 300 adults with different types of SCA are randomly assigned to take either troriluzole or a placebo dail…
Phase: PHASE3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill could slow MS relapses and disability
Disease control OngoingThis Phase 3 trial tests whether the oral drug remibrutinib works better than teriflunomide at reducing relapses and slowing disability in people with relapsing multiple sclerosis. About 1,000 adults aged 18–55 with active MS are taking part. The study is double-blind, meaning ne…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Stem cell transplant offers new hope for kids with rare immune diseases
Disease control OngoingThis study tests a donor stem cell transplant for people with severe immune system problems, like SCID and Wiskott-Aldrich syndrome. The goal is to help the body make healthy blood cells and fight infections. Participants receive donated stem cells to rebuild their immune system.…
Phase: NA • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New antibody aims to block muscle wasting in rare disease
Disease control OngoingThis Phase 2 trial tests a drug called RO7204239 in 51 adults with facioscapulohumeral muscular dystrophy (FSHD), a genetic condition that causes progressive muscle weakness. The drug is an antibody that blocks myostatin, a protein that normally limits muscle growth, to help pres…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Gene therapy RGX-202 made available for single patients in need
Disease control TEMPORARILY_NOT_AVAILABLEThis program allows eligible patients to receive RGX-202, a gene therapy, on a single-patient basis outside of a clinical trial. It is designed for those with serious conditions who have no other treatment options. Currently, the program is temporarily not available.
Sponsor: REGENXBIO Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a common MS drug help people with a rare nerve disease walk better?
Disease control OngoingThis clinical trial is testing whether dimethyl fumarate, a drug already used for multiple sclerosis, can improve balance and walking in adults with adrenomyeloneuropathy (AMN), a rare nerve disease. Forty participants will take either the drug or a placebo daily for 36 months, w…
Phase: PHASE2, PHASE3 • Sponsor: Pujol, Aurora, M.D. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Gene therapy trial aims to halt Muscle-Wasting disease
Disease control OngoingThis study tests a gene therapy called vesemnogene lantuparvovec in about 20 people with spinal muscular atrophy (SMA), a genetic condition that causes muscle weakness. The therapy delivers a working copy of the SMN1 gene to help muscles work better. The main goal is to check saf…
Phase: PHASE1, PHASE2 • Sponsor: Lantu Biopharma • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for duchenne: experimental drug aims to restore muscle protein
Disease control OngoingThis early-stage trial is testing a drug called NS-050/NCNP-03 in 20 boys with Duchenne muscular dystrophy (DMD) who have a specific genetic mutation. The drug is designed to skip a faulty section of the dystrophin gene, allowing the body to produce a shorter but still functional…
Phase: PHASE1, PHASE2 • Sponsor: NS Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New Muscle-Boosting drug combo tested for SMA
Disease control OngoingThis study tests whether adding an experimental drug (RO7204239) to an existing SMA medicine (risdiplam) can help people with spinal muscular atrophy build stronger muscles and move better. The trial includes about 259 children and young adults, ages 2 to 25, who can walk. Resear…
Phase: PHASE2, PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Could a drug slow rare brain disease? new study uses Real-World data to find out
Disease control OngoingThis study looks at whether the drug troriluzole can slow the progression of spinocerebellar ataxia (SCA), a rare genetic disease that affects movement and balance. Researchers will compare 909 patients who took troriluzole for up to three years with similar patients who did not …
Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Heart cell therapy shows promise for duchenne MD in major trial
Disease control OngoingThis Phase 3 trial tests a cell therapy called deramiocel (CAP-1002) in 106 boys and young men with Duchenne muscular dystrophy. Participants receive either the cell therapy or a placebo every 3 months for a year, then all can receive the therapy for another year. The goal is to …
Phase: PHASE3 • Sponsor: Capricor Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Can a drug stop amyloid damage after a heart transplant?
Disease control OngoingThis study tests whether the drug tafamidis can safely stop the progression of ATTR amyloidosis in people who have already received a heart transplant. About 25 stable patients will take tafamidis daily for 12 months. Researchers will measure changes in blood protein levels, nerv…
Phase: PHASE4 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug cocktail aims to outsmart resistant ovarian cancer
Disease control OngoingThis Phase 2 trial tests two experimental drug combinations in 63 women with a specific type of ovarian cancer (BRCA-mutant or HRD-positive) that has worsened after prior PARP inhibitor treatment. Participants receive either tuvusertib plus niraparib or tuvusertib plus larteserti…
Phase: PHASE2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Gene therapy trial aims to slow duchenne muscular dystrophy in boys
Disease control OngoingThis study tests a single dose of SGT-001 gene therapy in 12 boys (children and teens) with Duchenne muscular dystrophy. The main goal is to check safety and how well the body tolerates the treatment. Participants will be followed for about 5 years to monitor side effects and any…
Phase: PHASE1, PHASE2 • Sponsor: Solid Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Gene therapy after stem cell transplant shows promise for rare brain disease
Disease control OngoingThis study tests a one-time gene therapy infusion (FBX-101) given after a standard stem cell transplant in 6 children with infantile Krabbe disease, a severe genetic disorder affecting the nervous system. The therapy uses a harmless virus to deliver a working copy of the GALC gen…
Phase: PHASE1, PHASE2 • Sponsor: Forge Biologics, Inc • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug shows promise for SMA patients in major trial
Disease control OngoingThis study tests whether adding taldefgrobep alfa to standard SMA treatments can improve muscle function in people with spinal muscular atrophy (SMA). About 269 participants, both walkers and non-walkers, will receive either the drug or a placebo for 48 weeks. The main goal is to…
Phase: PHASE3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Gene therapy hope for SMA kids: early trial launches
Disease control OngoingThis early-stage trial tests a new gene therapy called NKG001 in 21 children under 5 with spinal muscular atrophy (SMA). The therapy is given as a single dose, either through a vein or combined with a spinal injection. The main goal is to check safety and find the best dose, not …
Phase: NA • Sponsor: Nikegen Pharmaceutical (Hangzhou) Company Limited • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill could tame MS relapses
Disease control OngoingThis Phase 3 trial tests remibrutinib, an oral tablet, against teriflunomide in 1000 adults with relapsing multiple sclerosis. The goal is to see if remibrutinib better reduces yearly relapse rates and delays disability. Participants will then have the option to continue remibrut…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Promising drug for rare nerve disease trial pulled before start
Disease control TerminatedThis study was designed to test whether the drug govorestat could improve symptoms of Charcot-Marie-Tooth disease caused by sorbitol dehydrogenase deficiency (CMT-SORD), a rare nerve condition. It planned to enroll people aged 16 to 65 and compare govorestat to a placebo over 36 …
Phase: PHASE3 • Sponsor: Applied Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Experimental combo targets Hard-to-Treat lung cancer
Disease control OngoingThis study tests a new drug, Tuvusertib, combined with an immunotherapy called Cemiplimab in people with a specific type of advanced lung cancer (non-squamous non-small cell) that has worsened after prior treatments. The trial aims to see if the combination can shrink tumors and …
Phase: PHASE1, PHASE2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Gene therapy breakthrough? new trial targets duchenne muscular dystrophy
Disease control OngoingThis Phase 3 trial tests a gene therapy called SRP-9001 for Duchenne muscular dystrophy (DMD), a severe muscle-wasting disease. It includes 148 males who can and cannot walk. Participants receive a one-time IV infusion of the therapy or a placebo, and are followed for about 128 w…
Phase: PHASE3 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Hearing loss injection study pulled before it began
Disease control TerminatedThis pilot study aimed to test whether a mixture of dexamethasone, hyaluronic acid, and a green dye could be safely injected into the ear to treat certain types of hearing loss that don't improve with standard treatments. The plan was to enroll 26 adults with sudden hearing loss,…
Phase: PHASE1, PHASE2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Higher dose of spinraza tested in SMA patients who already tried risdiplam
Disease control OngoingThis study tests a higher dose of nusinersen (Spinraza) in 45 teenagers and adults with spinal muscular atrophy (SMA) who cannot walk and have already taken risdiplam. Participants receive two 50 mg loading doses two weeks apart, then 28 mg every four months for about two years, …
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New pill aims to slow muscle damage in becker MD
Disease control OngoingThis phase 2 trial tests a daily oral drug called sevasemten (EDG-5506) in 244 adults and adolescents with Becker muscular dystrophy, a condition that causes progressive muscle weakness. The study compares the drug to a placebo to see if it can reduce muscle damage, improve walki…
Phase: PHASE2 • Sponsor: Edgewise Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Can a cochlear implant bring back hearing after tumor removal?
Disease control OngoingThis study tests whether a cochlear implant can safely and effectively restore hearing in people who become deaf in one ear after surgery to remove a benign tumor (vestibular schwannoma) or to treat Meniere's disease. Fifteen participants will receive the implant during their sur…
Phase: NA • Sponsor: Ohio State University • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Could an arthritis drug help kids with duchenne MD? new trial aims to find out
Disease control OngoingThis study tests satralizumab, a drug that calms inflammation, in 30 children aged 8 to 17 with Duchenne muscular dystrophy. The goal is to see if it improves bone density and muscle function. Participants receive injections for several months while continuing standard steroid th…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Could a single gene injection slow frontotemporal dementia?
Disease control OngoingThis early-stage trial tests a gene therapy called PBFT02 for frontotemporal dementia (FTD) in people with specific genetic mutations. The therapy delivers a working copy of the GRN gene directly into the brain. The study involves 30 adults and primarily checks for safety and sid…
Phase: PHASE1, PHASE2 • Sponsor: Passage Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for DMD: Long-Term trial of weekly infusions begins
Disease control ENROLLING_BY_INVITATIONThis study is for people with Duchenne muscular dystrophy (DMD) who have already taken part in a previous trial of BMN 351. It tests the long-term safety of weekly intravenous infusions of BMN 351 and whether it helps maintain physical function. Only 18 participants will be enrol…
Phase: PHASE2 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for FSHD: Long-Term drug safety trial underway
Disease control OngoingThis study is for people with FSHD, a genetic disease that causes muscle weakness. It tests the long-term safety and how well the body tolerates a drug called AOC 1020, given through a vein. About 84 adults who completed a previous study will take part. The main goal is to check …
Phase: PHASE2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Gene therapy trial targets duchenne in toddlers
Disease control OngoingThis study tests a gene therapy called delandistrogene moxeparvovec in 13 children under age 4 with Duchenne muscular dystrophy. The goal is to see if it is safe and can help produce a key muscle protein. The children will be followed for about 5 years.
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Hope for becker MD: new drug shows promise in Long-Term trial
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety and effects of a drug called EDG-5506 (sevasemten) in people with Becker muscular dystrophy, a muscle-weakening disease. About 260 adults and teens who were in earlier EDG-5506 studies will take the drug and be monitored for side effects a…
Phase: PHASE2 • Sponsor: Edgewise Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Gene therapy vs. standard care: new study tracks Long-Term outcomes in duchenne patients
Disease control ENROLLING_BY_INVITATIONThis study follows 500 people with Duchenne muscular dystrophy to see how well a gene therapy (ELEVIDYS) works compared to standard steroid treatment over time. Researchers will measure movement abilities, breathing, and safety, including liver problems. Participants must already…
Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Early access to experimental SMA drug apitegromab offered before approval
Disease control NO_LONGER_AVAILABLEThis expanded access program provides apitegromab, an experimental drug that blocks myostatin to help maintain muscle strength, to eligible patients with spinal muscular atrophy (SMA) before it is officially approved. Participants must be at least 2 years old and have a confirmed…
Sponsor: Scholar Rock, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Could a headset tame inflammation in duchenne muscular dystrophy?
Disease control ENROLLING_BY_INVITATIONThis pilot study tests a device called Travagus One, which stimulates a nerve in the ear to reduce inflammation in boys with Duchenne muscular dystrophy (DMD). Twenty boys aged 5-17 will use the headset at home for 5 minutes twice a day for one week. Researchers will measure infl…
Phase: NA • Sponsor: taVNS AB • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New study tracks bone safety of DMD drug vamorolone over years
Disease control OngoingThis study follows about 80 boys with Duchenne muscular dystrophy who have already taken vamorolone in earlier studies. Researchers want to see how safe the drug is over a longer time, especially its effect on bone health, like spine fractures. The boys continue taking vamorolone…
Phase: PHASE4 • Sponsor: Santhera Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Cancer drug shows promise for rare blood vessel disorders in kids and young adults
Disease control OngoingThis study tests the drug alpelisib, already approved for some breast cancers, in people aged 2 months to 30 years with certain blood vessel growth disorders caused by PIK3CA or TIE2 gene changes. Participants take the drug for 2-3 years and attend up to 16 clinic visits to check…
Phase: PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug SAT-3247 tested for long-term muscle protection in duchenne MD
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety and effects of a drug called SAT-3247 in 10 people with Duchenne muscular dystrophy who were in a previous trial. Participants take the drug by mouth five days a week for about 11 months. Researchers will check for side effects and measure…
Phase: PHASE2 • Sponsor: Satellos Bioscience, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for DM1: Long-Term trial of AOC 1001 underway
Disease control ENROLLING_BY_INVITATIONThis phase 3 study is testing the long-term safety and effectiveness of an experimental drug called AOC 1001 (del-desiran) for people with myotonic dystrophy type 1 (DM1), a genetic muscle disorder. The trial enrolls 230 adults who have completed a prior AOC 1001 study and will r…
Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
SMA drug risdiplam under Long-Term watch: will it hold up?
Disease control OngoingThis study follows 403 adults and children with spinal muscular atrophy who are already taking risdiplam (Evrysdi) as prescribed by their doctor. Researchers will track side effects and how well the drug works over about two years. The goal is to see if risdiplam remains safe and…
Phase: PHASE4 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Experimental spinal injection aims to keep kids with rare disease moving
Disease control OngoingThis study tests a drug called SHP611, given as a spinal injection, in 36 children with late infantile metachromatic leukodystrophy (MLD), a rare and severe brain disease. The main goal is to see if the treatment helps children keep their ability to walk and move for as long as p…
Phase: PHASE2 • Sponsor: Shire • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Last chance access: vatiquinone for mitochondrial disease patients
Disease control NO_LONGER_AVAILABLEThis program offered vatiquinone, an experimental liquid medication, to patients with inherited mitochondrial diseases like Leigh syndrome who had already completed a previous safety study. The goal was to continue treatment for those who might benefit, but enrollment is now clos…
Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug GRT6019 takes first step toward duchenne treatment
Disease control OngoingThis early-phase trial tests the safety and tolerability of a new drug called GRT6019 in 24 healthy men. Participants receive multiple doses over 4 weeks and are monitored for side effects and how the drug moves through the body. The goal is to see if GRT6019 is safe enough to st…
Phase: PHASE1 • Sponsor: Grünenthal GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug shows promise in preventing SMA in newborns
Disease control OngoingThis study tests the drug risdiplam (Evrysdi) in infants up to 6 weeks old who have a genetic diagnosis of spinal muscular atrophy (SMA) but no symptoms yet. The goal is to see if early treatment can help them reach motor milestones like sitting without support. The trial involve…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Experimental drug hopes to slow rare muscle disease in two patients
Disease control ENROLLING_BY_INVITATIONThis early-stage trial tests a daily injection of ASA-001 in two adults with a rare genetic muscle disease (ADSS1 deficient myopathy). The main goals are to see if the drug is safe and if it can slow the disease. Participants will take the drug for 8 months and have clinic visits…
Phase: PHASE1 • Sponsor: Cure ADSSL1 • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug shows promise for stubborn cancers
Disease control OngoingThis study tests a new drug called 9-ING-41, given alone or with chemotherapy, in adults with cancers that have not responded to standard treatments. The goal is to see if the drug is safe and can help control the disease. About 350 people with various advanced cancers, including…
Phase: PHASE2 • Sponsor: Actuate Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Can a shot stop ALS before it starts? new trial tests tofersen in gene carriers
Disease control OngoingThis phase 3 trial tests whether the drug tofersen can delay or prevent ALS in adults who carry a SOD1 gene mutation but have no symptoms yet. About 158 participants will receive either tofersen or a placebo, and researchers will track how many develop ALS within two years. The g…
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Could a common drug help kids with rare leigh syndrome?
Disease control ENROLLING_BY_INVITATIONThis study tests the drug sirolimus (rapamycin) in 15 people aged 6 months to 55 years with genetically confirmed Leigh syndrome, a rare and serious mitochondrial disease. The goal is to see if the drug is safe and can help with symptoms like muscle weakness and developmental del…
Phase: PHASE2 • Sponsor: Matthew Demczko • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Gene therapy for duchenne MD: Long-Term Follow-Up begins
Disease control ENROLLING_BY_INVITATIONThis study follows 66 boys with Duchenne muscular dystrophy who previously received RGX-202 gene therapy. Researchers will monitor side effects and measure muscle function over time, such as how fast they can stand, walk, or climb. The goal is to see if the treatment remains safe…
Sponsor: REGENXBIO Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control TerminatedThis study tests an oral drug called emavusertib (CA-4948) in adults with acute myeloid leukemia (AML) or a high-risk bone marrow disorder (MDS) that have not responded to or returned after prior treatment. The goal is to find the safest and most effective dose and to see if the …
Phase: PHASE1, PHASE2 • Sponsor: Curis, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Painless eye drops could save sight in kids with brain tumors
Disease control OngoingThis study tests a new painless nerve growth factor eye drop (CHF6467) in 36 children and young adults with optic pathway glioma, a brain tumor that often causes vision loss. The goal is to see if the drops can protect or improve vision without the pain side effects of standard n…
Phase: PHASE2 • Sponsor: Benedetto Falsini • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Gene therapy hope for duchenne boys in first human test
Disease control OngoingThis early-stage trial tests a single dose of a gene therapy called JWK007 in 3 boys aged 5-10 with Duchenne muscular dystrophy. The main goal is to check safety and tolerability, while also looking at whether it helps muscle function. It is a very small, first-in-human study, so…
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Can intensive therapy boost motor skills in kids with SMA?
Disease control OngoingThis pilot study tests whether combining intensive hand-arm and leg therapy with strength training can improve motor function in children with spinal muscular atrophy (SMA). Five children will attend one 6-hour session each weekend for 15 weeks. Researchers will check if the ther…
Phase: NA • Sponsor: Teachers College, Columbia University • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for duchenne: Long-Term drug safety trial underway
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of an experimental drug called WVE-N531 in people with Duchenne muscular dystrophy (DMD) who have already taken it in a previous study. About 175 participants will receive the drug and be monitored for side effects, heart and lung function…
Phase: PHASE2 • Sponsor: Wave Life Sciences USA, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
One-Time gene therapy aims to halt rare muscle disease
Disease control OngoingThis study tests a single dose of SRP-9003 gene therapy in 17 people with limb girdle muscular dystrophy 2E/R4, a genetic muscle-weakening disease. The goal is to restore a missing protein in muscle cells and improve muscle function. Both walkers and non-walkers can join, and the…
Phase: PHASE3 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Gene therapy hope for boys with duchenne muscular dystrophy
Disease control OngoingThis study tests a gene therapy called PF-06939926 in 114 boys with Duchenne muscular dystrophy (DMD), a severe muscle-wasting disease. Two-thirds receive the gene therapy, while one-third get a placebo, but can switch to the real treatment after one year. The main goal is to see…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Higher dose of muscular dystrophy drug shows promise in new trial
Disease control OngoingThis Phase 3 trial tests whether higher doses of eteplirsen (Exondys 51) can safely improve muscle function in boys with Duchenne muscular dystrophy whose genetic mutation allows exon 51 skipping. About 160 ambulatory boys will receive one of three doses (30, 100, or 200 mg/kg) t…
Phase: PHASE3 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Vutrisiran shows promise for Long-Term control of rare heart condition
Disease control ENROLLING_BY_INVITATIONThis study is for people with a rare heart condition called ATTR amyloidosis with cardiomyopathy, where abnormal protein builds up in the heart. It tests the long-term safety and effectiveness of a drug called vutrisiran, given as an injection every three months. About 700 adults…
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Experimental gene therapy targets rare muscle disease in first human test
Disease control OngoingThis early-phase trial tests a single-dose gene therapy called SRP-9003 in 6 people with limb girdle muscular dystrophy type 2E/R4, a rare genetic muscle-weakening disease. The main goals are to check safety and see if the therapy can produce the missing beta-sarcoglycan protein …
Phase: PHASE1 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Promising Gene-Targeting drug for ALS enters final trial phase
Disease control OngoingThis study tests an experimental drug called ION363 in people with a rare, inherited form of ALS caused by FUS gene mutations. The goal is to see if the drug can slow the disease and help people live longer. About 89 participants will receive the drug via spinal injection. This i…
Phase: PHASE3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Milder stem cell transplant shows promise for kids with immune disorders
Disease control OngoingThis study tests a stem cell transplant using a milder chemotherapy-like regimen to treat children and young adults (up to age 28) with various immune system disorders. The goal is to help the donor stem cells settle in the body with fewer side effects. The study involves 20 part…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Higher doses of SMA drug tested for Long-Term safety
Disease control OngoingThis long-term study is testing higher doses of nusinersen (Spinraza) in people with spinal muscular atrophy who already completed a previous nusinersen study. The main goal is to check safety over several years, including side effects, heart health, and growth. Participants rece…
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Could mild low-oxygen air boost nerve repair without surgery?
Disease control ENROLLING_BY_INVITATIONThis study tests whether breathing short bursts of air with slightly less oxygen can help nerves in the hand heal better after injury. The therapy is non-invasive and aims to improve hand function and reduce pain. About 80 adults with severe carpal tunnel syndrome will be enrolle…
Phase: NA • Sponsor: University of Alberta • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Gene therapy hope for kids with rare muscle-wasting disease
Disease control OngoingThis early-stage trial tests a single intravenous dose of a gene therapy (ATA-200) in 4 children aged 6-12 with limb-girdle muscular dystrophy type 2C/R5 (LGMD2C), a rare genetic muscle-weakening condition. The goal is to see if the treatment is safe and tolerable by delivering a…
Phase: PHASE1 • Sponsor: Atamyo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Hope for muscle strength: new drug targets myotonic dystrophy
Disease control OngoingThis phase 3 trial tests an experimental drug called AOC 1001 in 159 adults with myotonic dystrophy type 1, a genetic condition that causes muscle weakness and stiffness. Participants receive either the drug or a placebo by intravenous infusion. The main goal is to see if the dru…
Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New RNA drug hopes to slow duchenne muscle loss
Disease control OngoingThis early-phase trial tests a new drug called RAG-18 in 12 boys aged 4-15 with Duchenne muscular dystrophy. The drug is a small activating RNA given through an IV, designed to help muscles work better. The main goal is to check safety and how the body handles the drug, with earl…
Phase: EARLY_PHASE1 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Hope for rare heart disease: new drug aims to slow deadly protein clumps
Disease control OngoingThis study tests a drug called vutrisiran in 655 adults with a rare heart condition caused by abnormal protein buildup (ATTR amyloidosis with cardiomyopathy). The drug is given as a shot every 3 months and aims to reduce deaths and heart-related hospital stays. The goal is to see…
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New stem cell approach aims to tame rare genetic diseases
Disease control OngoingThis study tests a stem cell transplant method for people with inherited metabolic disorders and severe osteopetrosis. The goal is to get the donor cells to take hold while keeping side effects low. Participants receive chemotherapy drugs before the transplant to prepare their bo…
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New pill takes on Hard-to-Treat cancers in first human trial
Disease control OngoingThis early-stage trial tests an experimental oral drug called PRJ1-3024 in 39 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug may s…
Phase: PHASE1 • Sponsor: Zhuhai Yufan Biotechnologies Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug shows promise for Long-Term control of rare nerve disease
Disease control OngoingThis study looks at the long-term safety and effects of a drug called eplontersen in people with a rare inherited nerve disease called hATTR-PN. About 151 participants who completed earlier studies will receive regular injections of eplontersen. The goal is to see if the drug rem…
Phase: PHASE3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Could a common diabetes drug help fight ALS?
Disease control OngoingThis study tests whether metformin, a widely used diabetes drug, is safe for people with a specific genetic form of ALS (C9orf72). Over 24 weeks, 41 participants will take metformin to see if it reduces toxic proteins linked to the disease. The goal is to determine if metformin c…
Phase: PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
SPINRAZA study tracks movement in adults with spinal muscular atrophy
Disease control OngoingThis study follows 20 adults with spinal muscular atrophy (SMA) type II who are already taking SPINRAZA. Researchers will measure motor function using a 32-point scale over 27 months to see if the drug helps maintain or improve movement. The goal is to better understand how SPINR…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Gene therapy boost for krabbe patients after transplant
Disease control OngoingThis early-phase trial tests a single infusion of a gene therapy called FBX-101 in 9 people with Krabbe disease who have already received a stem cell transplant. The therapy uses a harmless virus to deliver a working copy of the GALC gene, aiming to improve motor function and saf…
Phase: PHASE1, PHASE2 • Sponsor: Forge Biologics, Inc • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Gene therapy hope for babies with fatal muscle disease
Disease control OngoingThis study tests a new gene therapy called SKG0201 in 12 infants with spinal muscular atrophy type 1, a severe muscle-weakening disease. The treatment aims to improve survival and motor skills by delivering a working gene. Researchers are checking safety and how well the therapy …
Phase: NA • Sponsor: Kun Sun • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
MS patients switch meds: will a cheaper option work just as well?
Disease control OngoingThis study looks at people with relapsing-remitting multiple sclerosis who switched from the drug MabThera to a similar, lower-cost medicine called Rixathon. Researchers want to see if the switch changes signs of nerve damage, new brain lesions, relapses, or disability. They will…
Sponsor: Uppsala University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Could a common mineral slow Parkinson's? new trial begins
Disease control ENROLLING_BY_INVITATIONThis study is testing whether low-dose lithium aspartate, a dietary supplement, can slow the progression of Parkinson's disease. It involves 35 people who have already completed a lithium trial, and they will take lithium for another 24 weeks. Researchers will use brain scans and…
Phase: PHASE1, PHASE2 • Sponsor: State University of New York at Buffalo • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug trial hopes to slow muscle damage in kids with DMD
Disease control OngoingThis study tests an experimental drug called sevasemten in 76 children aged 4-9 with Duchenne muscular dystrophy. The goal is to check the drug's safety, how the body processes it, and its effect on muscle health markers. Participants are randomly assigned to receive the drug or …
Phase: PHASE2 • Sponsor: Edgewise Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
One-Person trial aims to treat rare nerve disorder with custom drug
Disease control ENROLLING_BY_INVITATIONThis study tests a custom-made drug called an antisense oligonucleotide (ASO) designed for one person with Charcot-Marie-Tooth disease type 2D (CMT2D) caused by a specific GARS1 gene mutation. The drug aims to improve motor skills and quality of life. Only one participant is enro…
Phase: PHASE1, PHASE2 • Sponsor: n-Lorem Foundation • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New hope for duchenne kids: drug combo after gene therapy tested
Disease control OngoingThis study tests an experimental drug called EDG-5506 (sevasemten) in 43 children and teens aged 6 to 17 with Duchenne muscular dystrophy who have already received gene therapy. The goal is to see if the drug is safe and how it affects muscle damage markers. Participants are rand…
Phase: PHASE2 • Sponsor: Edgewise Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Hope for duchenne: new cell therapy shows promise in Long-Term trial
Disease control OngoingThis study tests the long-term safety and effectiveness of a cell therapy called deramiocel (CAP-1002) in people with Duchenne muscular dystrophy who completed the earlier HOPE-2 trial. Participants receive an infusion of deramiocel every 3 months for about 5 years, with the opti…
Phase: PHASE2 • Sponsor: Capricor Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
One-Patient trial hopes to fix rare nerve disease at its genetic root
Disease control OngoingThis study tests a custom-made drug (VCA-894A) in a single person with a rare genetic nerve disease called CMT2S. The drug is designed to correct a specific genetic error and restore a missing protein. The main goals are to check if the treatment is safe and if it can improve mus…
Phase: PHASE1, PHASE2 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New gene therapy targets rare, aggressive ALS
Disease control OngoingThis early-stage trial tests a gene therapy called AMT-162 in 20 adults with a specific genetic form of ALS (SOD1-ALS). The treatment is given as a single injection into the spinal fluid. The main goal is to check safety and tolerability, while also looking for early signs that i…
Phase: PHASE1, PHASE2 • Sponsor: UniQure Biopharma B.V. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Gene therapy for rare brain diseases: 5-Year safety check begins
Disease control OngoingThis study follows 7 people who previously received a gene therapy called AXO-AAV-GM2 for Tay-Sachs or Sandhoff disease — rare, fatal genetic disorders that destroy nerve cells. Researchers will track them for up to 5 years to see if the treatment remains safe and whether it help…
Sponsor: Terence Flotte • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Experimental gene therapy targets rare muscle disease
Disease control OngoingThis early-stage trial tests a gene therapy called ATA-100 for people with LGMDR9, a rare genetic muscle disease that causes progressive weakness. Six adults receive a single intravenous infusion of the therapy, which delivers a working copy of the FKRP gene. The main goal is to …
Phase: PHASE1 • Sponsor: Atamyo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
One-Time gene injection aims to halt rare childhood paralysis
Disease control ENROLLING_BY_INVITATIONThis early-stage trial tests a single injection of gene therapy for people with SMARD1 or CMT2S, rare diseases caused by mutations in the IGHMBP2 gene. The therapy delivers a working copy of the gene directly into the spinal fluid. Ten participants, ranging from infants to childr…
Phase: PHASE1, PHASE2 • Sponsor: Megan Waldrop • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Desperate hope: stem cells tested on one child with rare muscle disease
Disease control NO_LONGER_AVAILABLEThis trial gives a single child with a rare form of congenital muscular dystrophy access to their own banked stem cells. The cells are given through 14 IV infusions to see if they are safe and can help control the disease. Because it involves only one patient, the results will be…
Sponsor: Hope Biosciences Research Foundation • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Desperate patient gets experimental stem cells for rare nerve disease
Disease control NO_LONGER_AVAILABLEThis study provides an experimental stem cell treatment (HB-adMSCs) to an 83-year-old man with Primary Lateral Sclerosis, a rare nerve disease that causes progressive muscle weakness. The patient's own banked stem cells are used, aiming to slow the disease. This is a single-patie…
Sponsor: Hope Biosciences Research Foundation • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Hope for rare muscle disease: new drug enters final testing phase
Disease control OngoingThis study tests a drug called BBP-418 (Ribitol) in 81 people aged 12 to 60 with limb girdle muscular dystrophy type 2I (LGMD2I), a genetic condition that causes progressive muscle weakness. Participants receive either the drug or a placebo for 36 months to see if it slows the di…
Phase: PHASE3 • Sponsor: ML Bio Solutions, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New drug targets genetic weakness in Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called pacritinib in people with advanced solid tumors (like breast cancer) that have a specific genetic change called 1q21.3 amplification. The goal is to see if the drug can shrink tumors or slow their growth. About 74 adults whose cancer has not respond…
Phase: PHASE1, PHASE2 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New combo shows promise for tough kidney cancers
Disease control OngoingThis study tests two drugs, nivolumab and cabozantinib, together in 60 people with advanced or metastatic non-clear cell kidney cancer. The goal is to see how well the combination shrinks tumors. Participants take cabozantinib daily and receive nivolumab infusions every two weeks…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Experimental drug shows promise in slowing duchenne muscle loss
Disease control OngoingThis study tests the long-term safety and effectiveness of an experimental drug called DS-5141b (Renadirsen) in 8 people with Duchenne muscular dystrophy who have already completed a previous study. Participants receive a weekly injection under the skin. Researchers will monitor …
Phase: PHASE2 • Sponsor: Daiichi Sankyo Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 18:48 UTC
-
New drug TAS-205 aims to help kids with duchenne walk better
Disease control OngoingThis Phase 3 trial tests whether TAS-205, an oral drug, can improve movement and safety in people with Duchenne muscular dystrophy. It includes 104 participants, both those who can walk and those who cannot. The study compares TAS-205 to a placebo over 52 weeks.
Phase: PHASE3 • Sponsor: Taiho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 15:28 UTC
-
Could a short pill course save hand function in advanced MS?
Disease control OngoingThis UK trial tests whether cladribine tablets, taken for just 8-10 days a year over two years, can slow the loss of hand function in people with advanced multiple sclerosis (MS). The study includes 204 participants with significant disability (EDSS 6.5-8.5). Half receive cladrib…
Phase: PHASE2, PHASE3 • Sponsor: Queen Mary University of London • Aim: Disease control
Last updated Jun 26, 2026 15:20 UTC
-
Gene therapy hope for rare brain disease in children
Disease control OngoingThis study tests a single infusion of OTL-200 gene therapy in 6 people with late juvenile metachromatic leukodystrophy (MLD), a rare genetic disease that damages the brain and nerves. The therapy uses the patient's own blood stem cells, modified to produce a missing enzyme. Resea…
Phase: PHASE3 • Sponsor: Orchard Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 13:33 UTC
-
Newborn screening study aims to catch rare diseases at birth
Diagnosis OngoingThis study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…
Sponsor: RTI International • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
Spit test could spot ALS early
Diagnosis OngoingThis study is testing whether a simple saliva sample can help diagnose amyotrophic lateral sclerosis (ALS). Researchers will analyze RNA in the saliva of 653 people, including ALS patients and healthy volunteers. If the test works, it could offer a faster, less invasive way to di…
Sponsor: ZIWIG • Aim: Diagnosis
Last updated Jun 27, 2026 12:01 UTC
-
Needle-Free carpal tunnel diagnosis on the horizon?
Diagnosis ENROLLING_BY_INVITATIONThis study explores whether ultrasound elastography, a non-invasive imaging technique, can accurately diagnose carpal tunnel syndrome (CTS) without the need for painful needle-based nerve tests. Researchers will enroll 80 participants—some with CTS and some healthy volunteers—to …
Sponsor: Da Nang Family General Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 11:04 UTC
-
Brain scan breakthrough could save babies from rare disease
Diagnosis OngoingThis study looks at whether a special brain scan called diffusion tensor imaging (DTI) can help doctors find Krabbe disease in newborns and decide who needs urgent treatment. About 100 babies with a positive newborn screen or family history of Krabbe disease will be scanned and f…
Sponsor: University of Pittsburgh • Aim: Diagnosis
Last updated Jun 27, 2026 09:11 UTC
-
Simple blood test could catch hidden heart disease in seniors
Diagnosis ENROLLING_BY_INVITATIONThis study is testing a way to find cardiac amyloidosis—a rare but serious heart condition—earlier in people aged 65 and older. Researchers in Turkey will screen 800 patients at family medicine clinics using simple blood tests and medical history. The goal is to see if this appro…
Sponsor: Kotyora Family Medicine Health Management and Education Association • Aim: Diagnosis
Last updated Jun 27, 2026 09:08 UTC
-
Algorithm aims to spot rare heart disease in medical records
Diagnosis TerminatedThis study aimed to test a computer algorithm that uses insurance claims data to identify people with ATTR amyloidosis, a rare disease that affects the heart and nerves. Researchers planned to check how well the algorithm worked by reviewing medical records. However, the study wa…
Phase: EARLY_PHASE1 • Sponsor: Yale University • Aim: Diagnosis
Last updated Jun 26, 2026 18:38 UTC
-
New test could predict falls in muscle disease patients
Diagnosis ENROLLING_BY_INVITATIONThis study aims to create a simple test battery to determine fall risk in people with neuromuscular disorders, such as muscular dystrophy or ALS. Researchers will assess 108 participants using several physical tests like walking, standing, and rising from a chair. The goal is to …
Sponsor: LMU Klinikum • Aim: Diagnosis
Last updated Jun 26, 2026 16:30 UTC
-
New york program offers extra screening for 100,000 newborns
Diagnosis ENROLLING_BY_INVITATIONScreenPlus is a large pilot program that offers families the option to have their newborn screened for a panel of rare genetic disorders, in addition to standard newborn screening. The study aims to screen 100,000 infants born at eight hospitals in New York. Researchers will eval…
Sponsor: Albert Einstein College of Medicine • Aim: Diagnosis
Last updated Jun 26, 2026 16:15 UTC
-
New study tests workplace coaching to keep Parkinson's patients on the job
Symptom relief OngoingThis study tests a personalized workplace intervention for 124 Dutch workers with Parkinson's disease, cerebellar ataxia, hereditary spastic paraparesis, or slowly progressive neuromuscular/mitochondrial disorders. A trained facilitator helps employees and their managers identify…
Phase: NA • Sponsor: Radboud University Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Ultrasound-Delivered pain gel shows promise for carpal tunnel sufferers
Symptom relief OngoingThis study tests whether a pain-relief gel (pregabalin) delivered through the skin using ultrasound can reduce pain and improve hand function in people with carpal tunnel syndrome. The treatment is given four times a week for a month, and compared to standard ultrasound therapy w…
Phase: NA • Sponsor: University of Faisalabad • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Could a home breathing program help kids with duchenne?
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether a 6-week, caregiver-assisted breathing program done at home with remote coaching is practical and helpful for children with Duchenne muscular dystrophy. Twelve children will do breathing exercises, airway clearance, and relaxation techniques at least 5 ti…
Phase: NA • Sponsor: Samsung Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
-
New combo therapy aims to stop the spins in common inner ear disorder
Symptom relief OngoingThis study tests whether adding balance training, education, and vestibular rehab to the standard Epley maneuver helps people with benign paroxysmal positional vertigo (BPPV) more than the maneuver alone. Forty-six adults with BPPV will receive either the combined approach or sta…
Phase: NA • Sponsor: Riphah International University • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
New nerve patch could ease pain after biopsy
Symptom relief OngoingThis study tests a biodegradable tube that is placed over a cut nerve during a leg biopsy. The goal is to see if it is safe and reduces common side effects like pain, redness, and swelling. Twenty adults with various nerve conditions are taking part, and half will get the tube wh…
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
Home exercise program shows promise for rare movement disorder
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether a 12-week strength and functional exercise program, done at home via video calls with a physiotherapist, can improve walking, balance, and daily life in people with Hereditary Spastic Paraplegia (HSP). Twenty participants aged 16 to 70 will each experienc…
Phase: NA • Sponsor: Hospital de Clinicas de Porto Alegre • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
Can a 12-Week online course help babies with SMA develop better?
Symptom relief OngoingThis study tests a 12-week online program for mothers of infants (12-36 months old) with SMA Type 1. The program aims to teach mothers how to support their baby's development and improve their own knowledge. Thirteen mothers will take part, with 10 receiving the program and 3 rec…
Phase: NA • Sponsor: Medipol University • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Can learning about pain or using tape ease carpal tunnel symptoms?
Symptom relief OngoingThis study tests two simple treatments for mild to moderate carpal tunnel syndrome: pain neuroscience education (learning how the brain processes pain) and kinesio taping (applying elastic tape to the wrist). Sixty adults aged 18 to 60 with symptoms for at least 3 months will rec…
Phase: NA • Sponsor: Middle East University • Aim: Symptom relief
Last updated Jun 27, 2026 12:10 UTC
-
Sugar water injection may ease carpal tunnel pain
Symptom relief OngoingThis study tests whether injecting a 5% dextrose (sugar water) solution around the nerve in the wrist can reduce pain and improve hand function in people with mild to moderate carpal tunnel syndrome. About 96 adults who haven't gotten better with standard care will receive the in…
Phase: NA • Sponsor: Antalya Training and Research Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
New dissolving film may stop dangerous episodes in rare nerve disease
Symptom relief ENROLLING_BY_INVITATIONThis study tests a medicated film placed under the tongue to quickly ease severe episodes (autonomic crises) in people with familial dysautonomia. The film contains dexmedetomidine, a drug that calms the body's stress response. Researchers will check if it reduces symptoms like h…
Phase: PHASE2 • Sponsor: NYU Langone Health • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Could a simple tourniquet change cut Post-Surgery pain and opioid use?
Symptom relief OngoingThis study tests whether using a lower-pressure tourniquet during orthopedic surgeries can reduce pain and the need for opioid painkillers afterward. Standard tourniquets use high pressure, which can cause muscle weakness and pain. The experimental device sets pressure based on t…
Phase: NA • Sponsor: The Methodist Hospital Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Mud vs. wax: which soothes carpal tunnel pain best?
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether warm paraffin wax baths or mud therapy (peloidotherapy) can reduce pain and improve hand function in people with mild to moderate carpal tunnel syndrome. Ninety adults will be split into three groups: one gets mud plus home exercises, another gets wax plu…
Phase: NA • Sponsor: Konya Beyhekim Training and Research Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
Carpal tunnel showdown: shots or knife?
Symptom relief OngoingThis study looks at two treatment plans for carpal tunnel syndrome, which causes hand numbness and pain. One plan starts with up to two steroid injections, then offers surgery if needed. The other plan goes straight to surgery. About 258 adults with mild to moderate symptoms will…
Phase: PHASE4 • Sponsor: Diakonhjemmet Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
Could a short steroid course after surgery reduce pain and nausea?
Symptom relief ENROLLING_BY_INVITATIONThis study looks at whether a 6-day course of oral steroids after orthopedic surgery can help reduce pain, nausea, and improve movement. About 500 adults having common surgeries like joint replacement or fracture repair will be randomly assigned to receive either standard care or…
Phase: PHASE4 • Sponsor: Emory University • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
Walking while counting: new training may boost brain and body in DMD boys
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether a dual-task training program—combining physical exercises like walking with mental tasks like counting—can improve both motor and cognitive function in 16 boys aged 6–12 with Duchenne muscular dystrophy. Participants will be randomly assigned to either st…
Phase: NA • Sponsor: Lokman Hekim University • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Hope for myotonic dystrophy: new drug shows promise in easing muscle stiffness Long-Term
Symptom relief ENROLLING_BY_INVITATIONThis study is testing the long-term safety and effectiveness of a drug called mexiletine PR for people with myotonic dystrophy types 1 and 2. The drug is taken once daily as a liquid to help reduce muscle stiffness (myotonia). The study includes 176 adults and teens who have alre…
Phase: PHASE3 • Sponsor: Lupin Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 08:14 UTC
-
Could a 12-minute electrical zap ease your numb fingers?
Symptom relief OngoingThis study looks at whether a type of electrical current called diadynamic current can reduce pain and improve hand function in people with carpal tunnel syndrome. About 80 adults with mild to moderate carpal tunnel syndrome will receive this therapy along with standard care like…
Phase: NA • Sponsor: Duzce University • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
Spinning chair could stop vertigo faster for BPPV patients
Symptom relief OngoingThis study tests two different head-and-body rotation procedures done in a mechanical chair to treat a common inner-ear condition called BPPV, which causes brief but intense spinning sensations. 128 adults with confirmed BPPV will be randomly assigned to either the standard Epley…
Phase: NA • Sponsor: Aalborg University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
Could body fat ease carpal tunnel pain? new study investigates
Symptom relief TerminatedThis study tests whether injecting a patient's own fat (lipografting) into the wrist can improve symptoms of mild to moderate carpal tunnel syndrome better than standard steroid injections. The fat is thought to reduce scarring and help nerves glide more freely. The trial plans t…
Phase: EARLY_PHASE1 • Sponsor: Columbia University • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
Robot suit helps kids with movement disorders take steps at home
Symptom relief OngoingThis study tests a wearable robotic exoskeleton called EXPLORER in 15 children with movement problems from conditions like cerebral palsy. The goal is to see if it helps them walk better in their everyday environments, such as home and the community. The study focuses on safety, …
Phase: NA • Sponsor: MarsiBionics • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Baking soda in numbing shots could ease carpal tunnel surgery pain
Symptom relief OngoingThis study tests whether adding sodium bicarbonate (baking soda) to the local anesthetic used during carpal tunnel release surgery reduces the pain of the injection itself. 116 adults with carpal tunnel syndrome will be randomly assigned to receive either buffered or standard ane…
Phase: NA • Sponsor: Kuopio University Hospital • Aim: Symptom relief
Last updated Jun 26, 2026 18:40 UTC
-
Which stitch leaves a better scar after carpal tunnel surgery?
Symptom relief OngoingThis study compares two common types of stitches used to close the wound after carpal tunnel release surgery: absorbable stitches that dissolve on their own and non-absorbable stitches that need to be removed. About 116 patients will be randomly assigned to one stitch type, and t…
Phase: NA • Sponsor: Kuopio University Hospital • Aim: Symptom relief
Last updated Jun 26, 2026 18:34 UTC
-
Can a multiple sclerosis drug help people with rare motor neuron disease walk better?
Symptom relief OngoingThis early-stage trial tests the drug dalfampridine (Ampyra), already used for multiple sclerosis, in 35 adults with primary lateral sclerosis or upper motor neuron ALS. The main goal is to see if it safely improves walking speed, measured by a timed 25-foot walk. Researchers wil…
Phase: PHASE1 • Sponsor: Hospital for Special Surgery, New York • Aim: Symptom relief
Last updated Jun 26, 2026 15:24 UTC
-
Zapped nerves: study planned to boost recovery after surgery — but never started
Knowledge-focused TerminatedThis study was designed to see if giving a short, mild electrical stimulation to compressed nerves during surgery could speed up recovery of strength and function. It planned to include people with nerve compression in the spine or limbs who were already scheduled for decompressi…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Scientists hunt for clues in genes and body fluids to unlock ALS mysteries
Knowledge-focused OngoingThis study is observing 217 people with ALS and related conditions like frontotemporal dementia and hereditary spastic paraplegia. Researchers aim to connect each person's genetic makeup with their symptoms and find biological markers in blood and spinal fluid. No new treatments …
Sponsor: University of Miami • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Biggest ALS gene study aims to unlock disease secrets
Knowledge-focused OngoingThis study looks at people with ALS and similar diseases like frontotemporal dementia and hereditary spastic paraplegia. Researchers want to understand how genes affect the disease and find biological markers (biomarkers) to help develop future treatments. About 708 participants,…
Sponsor: University of Miami • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Groundbreaking study aims to speed up ALS treatment development
Knowledge-focused OngoingThis study enrolls people with ALS and related disorders, as well as healthy volunteers, to track biological markers (biomarkers) in urine, blood, and spinal fluid. The goal is to better understand how these markers change over time, which could help design more effective future …
Sponsor: University of Miami • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study aims to sharpen tools for tracking becker muscular dystrophy
Knowledge-focused OngoingThis 24-month observational study will follow 80 people with Becker muscular dystrophy (BMD) to better understand how the disease progresses. Researchers will measure muscle strength, walking speed, breathing, and heart function using standard tests. The goal is to identify which…
Sponsor: Virginia Commonwealth University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Paving the way: new study aims to sharpen tools for LGMD R1 trials
Knowledge-focused OngoingThis 24-month observational study follows 100 people aged 12–50 with Limb Girdle Muscular Dystrophy type R1 (LGMD R1). Researchers will test whether a motor function scale called NSAD and muscle fat measurements from MRI can reliably track disease progression. The goal is to vali…
Sponsor: Virginia Commonwealth University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
New MRI coils aim to sharpen images for children
Knowledge-focused OngoingThis study tests new radio frequency coils for MRI scanners to see if they can produce better images in children, including those with Duchenne muscular dystrophy. Researchers will check for side effects like heating and discomfort, and measure image quality. The goal is to impro…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Massive study aims to unlock secrets of childhood nerve and muscle diseases
Knowledge-focused OngoingThis long-term study looks at children and adults with inherited nerve and muscle disorders that start early in life, like muscular dystrophy. Researchers will track symptoms over time and collect genetic samples from affected individuals, their family members, and healthy volunt…
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
New study tracks how DM1 affects chinese patients over time
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 1000 Chinese patients with myotonic dystrophy type 1 (DM1) to understand how the disease affects multiple body systems and leads to disability. Researchers will collect health data and blood samples every 3 to 6 months for several years. The goal is to identify…
Sponsor: Huashan Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Brain monitor may guide safer blood pressure during surgery
Knowledge-focused OngoingThis study looks at whether low blood pressure during major noncardiac surgery harms organs like the heart and kidneys. Researchers are using a non-invasive brain monitor to see if a personalized blood pressure target can be set. 650 patients at cardiovascular risk are being obse…
Sponsor: University Hospital, Basel, Switzerland • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Blood pressure clues may predict early death after heart attack
Knowledge-focused OngoingThis study examines whether a low pulse pressure (the difference between top and bottom blood pressure numbers) in the first hours after a cardiac arrest is linked to early death. Researchers will analyze data from 3500 patients who had a cardiac arrest outside the hospital and a…
Sponsor: Region Skane • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Brain scans reveal diabetes link to cognitive decline in rare disease
Knowledge-focused OngoingThis study looks at whether diabetes or blood sugar problems can worsen thinking and memory issues in people with myotonic dystrophy type 1. Researchers will use MRI brain scans and thinking tests over 4 years to track changes. The goal is to understand why some patients have mor…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Blood marker may predict nerve damage onset in rare genetic disease
Knowledge-focused OngoingThis observational study is looking at a protein called neurofilament light chain (NfL) in the blood of people who carry a gene variant for hereditary ATTR amyloidosis, both those without symptoms and those with nerve damage. Researchers want to see if NfL levels can help detect …
Sponsor: Alnylam Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Can a VR game make rehab fun for kids with duchenne?
Knowledge-focused ENROLLING_BY_INVITATIONThis study is testing a virtual reality game designed specifically for people with Duchenne muscular dystrophy (DMD). Six participants aged 7 and older will play the game once using a VR headset and hand tracking. Researchers will measure how easy and enjoyable the game is, and w…
Sponsor: Istanbul University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
French-Language scale for rare nerve disease put to the test
Knowledge-focused OngoingThis study checks whether a French version of a scale called PLSFRS works well for people with primary lateral sclerosis (PLS), a rare nerve disease. Researchers will ask 80 patients to fill out the questionnaire during routine check-ups every 3 to 6 months. The goal is to see if…
Sponsor: University Hospital, Tours • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Med student stress may be tied to wrist pain, new study suggests
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether anxiety and depression are connected to carpal tunnel syndrome in medical students. Researchers will measure the median nerve in the wrist and check students' anxiety and depression levels using questionnaires. The goal is to see if there is a link bet…
Sponsor: University of Ioannina • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New model aims to speed up rare disease diagnosis
Knowledge-focused OngoingThis study is testing a new way to care for people with rare diseases. It will use advanced genetic testing and a team of specialists to help diagnose patients faster and coordinate their care better. The study involves 136 participants with certain rare diseases and aims to redu…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Decision aids may ease patient uncertainty in hand surgery
Knowledge-focused TerminatedThis study tests whether giving patients with hand problems like carpal tunnel syndrome or trigger finger a decision aid—a booklet with clear information about their condition and treatment options—helps them feel more satisfied and less conflicted about their choices. About 126 …
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Can a simple scale accurately measure hand problems in carpal tunnel syndrome?
Knowledge-focused ENROLLING_BY_INVITATIONThis study is checking whether a questionnaire called the MAP-Hand scale is a valid and reliable way to measure hand activity in people with carpal tunnel syndrome. Researchers will enroll 180 adults with mild or moderate carpal tunnel syndrome and compare their scale results to …
Sponsor: Kirsehir Ahi Evran Universitesi • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Can a couple's lifestyle program reduce prostate cancer disparities?
Knowledge-focused OngoingThis study tests a lifestyle program for African American men who have finished prostate cancer treatment and their spouses or partners. The goal is to see if the program can improve quality of life, diet, physical activity, and partner support. Only 6 participants were enrolled,…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
New tools aim to speed up FSHD drug trials
Knowledge-focused OngoingThis study involves 324 adults with facioscapulohumeral muscular dystrophy (FSHD) across 14 international sites. Researchers are testing two new measurement tools—a functional test called FSHD-COM and a muscle-impedance device—to better track disease progression. The goal is to i…
Sponsor: University of Kansas Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
New study aims to uncover why people with muscle disease fall
Knowledge-focused OngoingThis study measures how often people with myotonic dystrophy type 1 fall and what factors affect their balance. Researchers will also assess fear of falling and leg muscle strength. The goal is to better understand fall risk in this condition.
Sponsor: Antalya Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
New study aims to catch brain damage in babies after heart surgery
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 30 infants with congenital heart disease who need heart surgery. Researchers will use blood tests, EEG brain wave monitoring, and MRI scans to look for signs of brain injury. The goal is to find better ways to detect brain damage early and identify which childr…
Sponsor: University Medical Centre Ljubljana • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Stitch showdown: which suture leaves a better scar after hand surgery?
Knowledge-focused TerminatedThis study aimed to see if using stitches that dissolve (absorbable) or stitches that need removal (non-absorbable) leads to better scar appearance and patient satisfaction after carpal tunnel or trigger finger surgery. It was planned for adults having these common hand surgeries…
Phase: NA • Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
New study probes arm muscle stiffness in duchenne patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how the muscles in the arms and hands change in people with Duchenne muscular dystrophy (DMD). Researchers will measure muscle tone, stiffness, and elasticity using a device called MyotonPRO. They will also test hand function and muscle strength. The goal is t…
Sponsor: Sanko University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Brain-Body link: new study explores thinking skills in kids with DMD
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how thinking skills (called executive functions) relate to everyday activities like self-care and play in children with Duchenne muscular dystrophy (DMD). Researchers will compare 38 children with DMD to healthy children using surveys and functional tests. The…
Sponsor: Lokman Hekim University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Researchers track Long-Term effects of duchenne gene therapy
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows about 400 people with Duchenne muscular dystrophy who have already received the gene therapy SRP-9001 in an earlier study. The goal is to monitor their safety and muscle function over time. No new treatment is given in this study.
Phase: PHASE3 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Thousands tracked after carpal tunnel surgery: does new device deliver?
Knowledge-focused OngoingThis study is tracking 2000 adults with carpal tunnel syndrome who are having surgery to release the nerve. The surgery uses a special device called UltraGuideCTR, which is guided by ultrasound. Researchers are collecting real-world data on symptoms and hand function for up to 24…
Sponsor: Sonex Health, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Scientists track rare eye disease to uncover clues for future treatments
Knowledge-focused OngoingThis study follows 46 people with gyrate atrophy, a rare genetic condition that causes vision loss, over 4 years. Researchers measure ornithine levels in the blood and track changes in the retina using eye scans and photos. The goal is to learn how the disease progresses under st…
Sponsor: Jaeb Center for Health Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:14 UTC
-
New ultrasound could better track carpal tunnel recovery
Knowledge-focused ENROLLING_BY_INVITATIONThis study tests a new ultrasound technique called shear wave elastography to measure stiffness in the wrist nerves and tissues of people with carpal tunnel syndrome. Researchers will compare these measurements with standard tests before and after treatment (surgery or steroid in…
Phase: NA • Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
New study tracks muscle decline in rare muscular dystrophy
Knowledge-focused OngoingThis study follows 25 people with limb-girdle muscular dystrophy type 2A (LGMD2A), a rare genetic disease that causes progressive muscle weakness. Researchers will measure how muscle strength changes over time and how it affects quality of life. The goal is to better understand t…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Scientists build heart cells in a dish to unravel genetic heart disease
Knowledge-focused ENROLLING_BY_INVITATIONThis study collects blood or skin samples from 100 adults with inherited heart rhythm disorders (like Long QT Syndrome or Brugada Syndrome) and healthy volunteers. Researchers will turn these samples into stem cells and then into heart cells to study how these diseases work and t…
Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Couples in cancer care: how stress and support shape health behaviors
Knowledge-focused OngoingThis study follows 200 African American prostate cancer survivors and their partners to understand how daily stress, social support, and lifestyle choices like physical activity and diet affect each other. Participants wear an activity tracker and answer surveys on their smartpho…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Massive gene hunt launched for mysterious mitochondrial diseases
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to discover new genetic mutations that cause mitochondrial disorders by analyzing tissue samples from up to 6,900 participants. It includes people with suspected or known mitochondrial diseases, such as MELAS or Leigh's Disease, who lack a genetic diagnosis. The r…
Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
Heart check: do Nerve-Targeting drugs also shield the heart in rare amyloidosis?
Knowledge-focused OngoingThis study follows 20 adults with hereditary transthyretin amyloidosis (ATTRv) who have both nerve and heart involvement. They are treated with patisiran or vutrisiran for two years. Researchers use MRI scans and questionnaires to see how the drugs affect heart structure and func…
Sponsor: Rennes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
New pathway aims to cut wait times for carpal tunnel patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether a new care pathway can shorten wait times for people with carpal tunnel syndrome. Researchers will compare wait times before and after the pathway is put in place. About 200 adults will take part and fill out a short satisfaction survey.
Sponsor: University of British Columbia • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Smart sleeve study aims to improve movement for nerve disease patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 1000 people with upper motor neuron disease who are about to receive the Cionic Neural Sleeve. The sleeve uses electrical stimulation to help muscles contract at the right time during movement. Researchers will track changes in health-related quality of life us…
Phase: NA • Sponsor: Cionic, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
New study aims to speed up FSHD drug development
Knowledge-focused OngoingThis study is working to create better tools for measuring muscle function in people with facioscapulohumeral muscular dystrophy (FSHD). Researchers will follow 100 adults with FSHD for up to 24 months, testing new ways to track disease progression. The goal is to make future cli…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Heart scans aim to uncover hidden damage in duchenne patients
Knowledge-focused TerminatedThis study was designed to track heart muscle changes in people with Duchenne muscular dystrophy using two cardiac MRIs taken two years apart, along with blood tests for heart failure markers. It planned to enroll participants aged 6 and older with a confirmed genetic diagnosis. …
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Scientists watch LGMD progress in 205 patients over years
Knowledge-focused OngoingThis study follows 205 people with four types of limb-girdle muscular dystrophy (LGMD) to understand how the disease changes over time. Participants will have their muscle strength, movement, and breathing tested regularly for up to 5 years. No treatment is given; the goal is to …
Sponsor: Sarepta Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
New study aims to map rare muscle disease progression
Knowledge-focused TerminatedThis study was designed to track the natural course of gamma-sarcoglycanopathy (LGMDR5), a rare muscle-weakening disease, over two years. Researchers planned to measure changes in muscle strength, walking ability, and daily function in patients aged 6 to 35. The goal was to bette…
Sponsor: Atamyo Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
New tools to track FSHD in wheelchair users
Knowledge-focused OngoingThis study aims to find better ways to measure disease progression in people with advanced facioscapulohumeral muscular dystrophy (FSHD) who use wheelchairs. Researchers will test various muscle strength and function tests over two years in 30 adults. The goal is to develop relia…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Standing wheelchairs for kids: a tiny study hopes to open doors
Knowledge-focused OngoingThis study looks at whether a power wheelchair that can lift a child from sitting to standing is practical for kids with conditions like cerebral palsy, spinal cord injuries, or genetic diseases. Only 4 children aged 5-17 are taking part. The goal is to see if the chair helps the…
Phase: NA • Sponsor: Grand Valley State University • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:22 UTC
-
Wearable sensors track tiny movements in SMA babies on Cutting-Edge therapies
Knowledge-focused OngoingThis study follows 35 infants with spinal muscular atrophy (SMA) who are receiving gene therapy or other advanced treatments. Researchers use small wearable motion sensors to measure how well the babies move their arms and legs over two years. The goal is to create a more precise…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:15 UTC
-
Real-World data sought on DMD Exon-Skipping drugs
Knowledge-focused ENROLLING_BY_INVITATIONThis observational study will follow 300 people with Duchenne muscular dystrophy who are already taking exon-skipping therapies (eteplirsen, golodirsen, or casimersen) as part of their routine care. Researchers will collect data on movement, lung function, and heart function over…
Sponsor: Sarepta Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:35 UTC
-
New study aims to design better braces for FSHD patients using MRI and motion capture
Knowledge-focused ENROLLING_BY_INVITATIONThis observational study will enroll 40 adults with facioscapulohumeral muscular dystrophy (FSHD) to understand how muscle degeneration affects movement. Researchers will use MRI to assess muscle health and 3D motion capture to analyze walking and posture. The goal is to create a…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:29 UTC
-
New registry tracks SMA in chinese kids to unlock Real-World insights
Knowledge-focused OngoingThis study is a registry that collects information on up to 600 children in China with spinal muscular atrophy (SMA). It aims to describe how the disease progresses and how treatments are used in everyday medical practice. The study does not test a new drug but gathers data to be…
Sponsor: Biogen • Aim: Knowledge-focused
Last updated Jun 26, 2026 12:32 UTC